GlassScriptPhysician profile
Catherine Jeans
NPI 1386488286
$683.29
in general payments reported to CMS, 2019-2025
17 companies · $583 in 2025
The $583 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $100 · 2025: $583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $683.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $683.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $118.22 | 2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $77.79 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $76.46 | 2025 | Airsupra, Farxiga |
| Exact Sciences Corporation | $50.61 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Abbvie INC. | $46.87 | 2024-2025 | |
| Dexcom, INC. | $42.27 | 2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $42.01 | 2024-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.88 | 2024-2025 | Jardiance |
| Astellas Pharma US INC | $29.74 | 2025 | Veozah |
| Amgen INC. | $29.11 | 2024-2025 | Otezla, Repatha, Evenity |
| Merck Sharp & Dohme LLC | $23.84 | 2025 | Capvaxive, Gardasil 9 |
| Sumitomo Pharma America, INC. | $21.39 | 2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $19.65 | 2025 | |
| Tactile Systems Technology INC | $19.50 | 2025 | Nimbl, Flexitouch Plus |
| Esperion Therapeutics, INC. | $17.60 | 2025 | Nexletol |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $17.37 | 2025 | Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.98 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Jeans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.